Angiotensin II human (TFA)
Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R) . Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human TFA also induces apoptosis. Angiotensin II human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway[1][2][3][4].
Product Specifications
CAS Number
[2761969-44-0]
Product Name Alternative
Angiotensin II (TFA) ; Ang II (TFA) ; DRVYIHPF (TFA)
UNSPSC
12352209
Target
Angiotensin Receptor; Apoptosis
Type
Peptides
Related Pathways
Apoptosis; GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Endocrinology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/angiotensin-ii-human-tfa.html
Purity
98.84
Solubility
H2O : 10 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CNC=N2)C(N3[C@@H](CCC3)C(N[C@@H](CC4=CC=CC=C4)C(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(O)=O)N.O=C(O)C(F)(F)F.[x]
Molecular Formula
C50H71N13O12.xC2HF3O2
Molecular Weight
1046.18 (free acid)
References & Citations
[1]de Gasparo M, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52 (3) :415-72.|[2]Fyhrquist F, et al. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995 Nov;9 Suppl 5:S19-24.|[3]Hu C, et al. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension. 2007;50 (5) :952-957.|[4]Nabah YN, et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation. 2004;110 (23) :3581-3586.|[5]Crowley SD, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006 Nov 21;103 (47) :17985-90.|[6]van Kats JP, et al. Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension. 1997 Jul;30 (1 Pt 1) :42-9.|[7]Daugherty A, et al. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000 Jun;105 (11) :1605-12.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Scientific Category
Peptides
Clinical Information
Launched
Isoform
AT1 Receptor; AT2 Receptor
Citation 01
J Healthc Eng. 2022 Jan 5:2022:1473597.|ACS Nano. 2022 Aug 23;16 (8) :12553-12568.|ACS Pharmacol Transl Sci. 2025 Jun 6;8 (7) :2048-2060.|Acta Pharm Sin B. 2022 Jan;12 (1) :135-148.|Acta Pharm Sin B. 2025 Mar;15 (3) :1643-1658.|Acta Pharmacol Sin. 2021 Jul;42 (7) :1090-1100.|Acta Pharmacol Sin. 2022 Oct;43 (10) :2573-2584.|Acta Pharmacol Sin. 2024 Aug;45 (8) :1618-1631.|Acta Pharmacol Sin. 2025 Apr;46 (4) :922-939.|Acta Pharmacol Sin. 2025 May;46 (5) :1275-1288.|Acta Pharmacol Sin. 2025 Sep 2.|Adv Sci (Weinh) . 2025 Jun 23:e07365.|Aging Med (Milton) . 2025 Oct 26;8 (5) :383-397.|Am J Physiol Cell Physiol. 2020 May 1;318 (5) :C913-C930.|Am J Physiol Cell Physiol. 2024 Feb 1;326 (2) :C400-C413.|Am J Physiol Heart Circ Physiol. 2018 Mar 1;314 (3) :H580-H592.|Am J Physiol Renal Physiol. 2021 Mar 1;320 (3) :F273-F284.|Arch Biol Sci. 2021 Jun.|Arch Physiol Biochem. 2025 Nov 24:1-19.|Artif Organs. 2025 Jul 5.|Atherosclerosis. 2025 Apr 26:405:119216.|Biochem Biophys Res Commun. 2021 Jun 11:557:77-84.|Biochem Biophys Res Commun. 2021 May 7:552:84-90.|Biochem Biophys Res Commun. 2024 Jan 22:693:149375.|Biochem Biophys Res Commun. 2024 Jul 26:735:150456.|Biochem Biophys Res Commun. 2025 Apr 1:755:151566.|Biochem Biophys Res Commun. 2025 Jan:745:151256.|Biochem Biophys Res Commun. 2025 May 8:770:151957.|Biochem Pharmacol. 2023 Jul:213:115631.|Biochem Pharmacol. 2024 Jan:219:115967.|Biochem Pharmacol. 2025 Apr:234:116800.|Biochem Pharmacol. 2025 Aug 19;242 (Pt 1) :117252.|Biochem Pharmacol. 2025 Aug 8;242 (Pt 1) :117218.|Biochem Pharmacol. 2025 Jul 26;242 (Pt 1) :117190.|Biochim Biophys Acta Mol Basis Dis. 2024 Feb 9;1870 (4) :167061.|Biochim Biophys Acta Mol Basis Dis. 2025 Jul 18;1871 (8) :167990.|Biochim Biophys Acta Mol Basis Dis. 2025 Jun;1871 (5) :167786.|Biochim Biophys Acta Mol Cell Res. 2024 Dec;1871 (8) :119852.|Biochim Biophys Acta Mol Cell Res. 2024 Mar;1871 (3) :119661.|Bioengineered. 2022 Feb;13 (2) :2597-2609.|Biomark Res. 2025 Mar 29;13 (1) :53.|Biomed Pharmacother. 2023 Dec:168:115729.|Biomed Pharmacother. 2023 Sep:165:115125.|Biomedicines. 2022 Dec 4;10 (12) :3131.|Biomolecules. 2022 Oct 27;12 (11) :1574.|Biomolecules. 2024 Jun 19;14 (6) :726.|bioRxiv. 2020 Mar.|bioRxiv. 2023 Oct 20.|bioRxiv. 2024 November 03.|BMC Cardiovasc Disord. 2021 May 31;21 (1) :266.|BMC Cardiovasc Disord. 2025 Jan 6;25 (1) :7.|Cardiovasc Diagn Ther. 2020 Apr;10 (2) :107-123. |Cardiovasc Drugs Ther. 2025 Nov 15.|Cardiovasc Innov Appl. 2023 Sep 13.|Cardiovasc Ther. 2025 Sep 13:2025:7230505.|Cardiovasc Toxicol. 2024 Sep;24 (9) :889-903.|Cell Biosci. 2025 Oct 22;15 (1) :143.|Cell Cycle. 2020 Oct;19 (20) :2734-2744.|Cell Death Differ. 2025 Nov 11.|Cell Death Discov. 2022 Apr 5;8 (1) :167.|Cell Death Discov. 2022 May 4;8 (1) :246.|Cell Host Microbe. 2022 Oct 12;30 (10) :1450-1463.e8.|Cell Mol Biol Lett. 2022 Jul 14;27 (1) :55.|Cell Mol Life Sci. 2023 Jun 20;80 (7) :184.|Cell Rep Med. 2025 Sep 16;6 (9) :102328.|Cell Signal. 2022 Aug 18;110443.|Cell Signal. 2024 Aug 20:111355.|Cell Signal. 2024 Jan:113:110974.|Cell Signal. 2024 Jul 14:121:111296.|Cell Signal. 2025 Jun 27:111968.|Cell Stem Cell. 2025 Sep 4;32 (9) :1390-1402.e9.|Cells. 2025 Apr 11;14 (8) :579.|Chin Chem Lett. 2023 Mar;34 (3) :107522.|Chin Med. 2025 Oct 23;20 (1) :180.|Circ Res. 2020 Mar 13;126 (6) :e15-e29.|Clin Exp Hypertens. 2023 Dec 31;45 (1) :2208774.|Clin Exp Hypertens. 2023 Dec 31;45 (1) :2284658.|Clin Transl Med. 2023 Mar;13 (3) :e1213.|Commun Biol. 2025 Jul 5;8 (1) :1009.|Commun Biol. 2025 Nov 29.|Dose Response. 2024 Oct 25;22 (4) :15593258241277919.|Dose Response. 2024 Oct 29;22 (4) :15593258241298062.|Elife. 2022 Jun 22:11:e74519.|EMBO Mol Med. 2025 Dec;17 (12) :3555-3585.|EMBO Rep. 2023 Mar 6;24 (3) :e56135.|Engineering. 2025 Nov 14.|Epigenomics. 2022 Mar;14 (5) :227-241.|ESC Heart Fail. 2025 Sep 3.|Eur J Cell Biol. 2024 May 28;103 (2) :151427.|Eur J Clin Invest. 2022 May 4; e13804.|Eur J Pharmacol. 2024 Apr 5:968:176397.|Eur J Pharmacol. 2025 Dec 15:1009:178388.|Exp Biol Med. 2020 Jun;245 (11) :983-993.|Exp Cell Res. 2023 May 1;426 (1) :113556.|Food Biosci. 2025 Mar.|Front Biosci (Landmark Ed) . 2025 Jun 25;30 (6) :37052.|Front Pharmacol. 2021 Jun 24:12:684375.|Front Pharmacol. 2022 Aug 17:13:942769.|Gene. 2023 Nov 15:885:147705.|Heliyon. 2023 May 26;9 (6) :e16619.|Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221136208.|Hum Mol Genet. 2024 Aug 31:ddae122.|Hypertens Res. 2023 Jul;46 (7) :1759-1770.|Hypertension. 2025 Sep;82 (9) :1505-1519.|Immun Inflamm Dis. 2023 Feb;11 (2) :e765.|In Vitro Cell Dev Biol Anim. 2025 Apr;61 (4) :374-388.|Inflammopharmacology. 2025 Jun;33 (6) :3349-3362.|Int Heart J. 2024;65 (3) :528-536.|Int Heart J. 2025 May 31;66 (3) :485-496.|Int Immunopharmacol. 2022 Nov:112:109218.|Int Immunopharmacol. 2023 Jun:119:110197.|Int Immunopharmacol. 2023 Mar:116:109795.|Int Immunopharmacol. 2024 Feb 15:128:111554.|Int Immunopharmacol. 2025 Sep 23:162:115163.|Int J Biochem Cell Biol. 2020 Apr;121:105703.|Int J Biol Macromol. 2025 Aug;320 (Pt 4) :146018.|Int J Biol Sci. 2025 Apr 22;21 (7) :3061-3080. |Int J Mol Sci. 2023 Jun 29;24 (13) :10839.|iScience. 2024 Jul 26;27 (9) :110594.|J Appl Pharm Sci. 2025 Jun;15 (06) :277-294.|J Appl Physiol (1985) . 2022 Jun 1;132 (6) :1460-1467.|J Bioenerg Biomembr. 2025 Jul 11.|J Cell Mol Med. 2019 Nov;23 (11) :7449-7461.|J Cell Mol Med. 2020 Apr;24 (8) :4748-4761.|J Cell Mol Med. 2024 Aug;28 (16) :e70022.|J Cell Mol Med. 2025 Jul;29 (14) :e70733.|J Funct Foods. 2023 Aug, 107, 105670.|J Mol Cell Cardiol. 2025 May:202:133-143.|J Mol Histol. 2025 Sep 3;56 (5) :290.|J Mol Med (Berl) . 2025 Aug 19.|J Neurovirol. 2025 Apr;31 (2) :170-186.|J Nucl Med. 2025 Sep 11:jnumed.124.268860.|J Nutr Biochem. 2024 Apr:126:109578.|J Pharmacol Sci. 2019 Sep;141 (1) :70-78.|J Physiol. 2025 May 11.|J Transl Med. 2025 Nov 13;23 (1) :1282.|J Vis Exp. 2025 May 16: (219) .|JCI Insight. 2020 Jul 9;5 (13) :e138505.|Kaohsiung J Med Sci. 2024 Jun;40 (6) :542-552.|Life Sci. 2022 Oct 15:307:120878.|Mar Drugs. 2025 Sep 19;23 (9) :365.|medRxiv. 2025 May 21.|Microorganisms. 2021 Feb 22;9 (2) :452.|Microvasc Res. 2020 Nov;132:104043.|Microvasc Res. 2022 Mar:140:104299.|Microvasc Res. 2022 Sep:143:104384.|Mol Biol Rep. 2024 Apr 15;51 (1) :506.|Mol Biol Rep. 2025 Aug 11;52 (1) :815.|Mol Cell Biol. 2024;44 (4) :149-163.|Mol Cell Endocrinol. 2023 Jul 1:571:111938.|Mol Cell Proteomics. 2025 Feb 5:100922.|Nat Aging. 2024 Mar;4 (3) :396-413.|Nat Commun. 2022 Jul 25;13 (1) :4278.|Nat Commun. 2023 Sep 21;14 (1) :5891.|Nat Commun. 2025 Jul 1;16 (1) :5927.|Nephrology (Carlton) . 2019 Nov;24 (11) :1103-1114.|Neuromolecular Med. 2025 Sep 15;27 (1) :64.|Oxid Med Cell Longev. 2019 Nov 23;2019:4025496.|Oxid Med Cell Longev. 2022 Feb 17:2022:3698219.|Patent. US20210277021A1.|Patent. US20230068165A1.|Patent. US20230071726A1.|Peptide Sci. 2025 Feb 25.|Pharmaceuticals (Basel) . 2025 Apr 9;18 (4) :553.|Pharmacol Res. 2021 Feb:164:105391.|Pharmacol Res. 2025 Apr:214:107675.|Physiol Res. 2020 Nov 16;69 (5) :813-822.|Phytomedicine. 2021 Oct:91:153675.|Phytomedicine. 2024 Apr:126:155200.|Phytomedicine. 2025 May:140:156545.|Phytomedicine. 2025 Oct:146:157101.|PLoS One. 2023 Sep 12;18 (9) :e0291469.|PLoS One. 2024 Jul 25;19 (7) :e0306137.|PLoS One. 2025 Sep 9;20 (9) :e0331471.|Ren Fail. 2023 Dec;45 (1) :2230318.|Res Sq. 2024 Jun 27.|Research Square Print. 2022.|Sci Adv. 2025 Jun 27;11 (26) :eadu8422.|Sci Rep. 2022 Jan 10;12 (1) :344.|Sci Rep. 2024 Apr 30;14 (1) :9960.|Sci Rep. 2024 Dec 5;14 (1) :30379.|Sci Rep. 2025 Feb 20;15 (1) :6200.|Sci Rep. 2025 Jul 2;15 (1) :22796.|Sci Transl Med. 2021 Jul 21;13 (603) :eaaz4959.|Sci Transl Med. 2024 May;16 (745) :eadh1763.|SSRN. 2023 Feb 14.|SSRN. 2024 Mar 8.|SSRN. 2025 Aug 13.|Talanta. 2024 Oct 14:282:127045.|Toxicol Appl Pharmacol. 2025 Aug 21:504:117528.|Ultrason Sonochem. 2025 Oct 20:123:107642.|View. 2025 Oct 28.|Br J Pharmacol. 2025 Aug 24.|Eur J Pharmacol. 2025 Feb 1:177346.|J Proteome Res. 2025 Nov 18.|Philos Trans R Soc Lond B Biol Sci. 2023 Jun 19;378 (1879) :20220173.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
